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Synthetic macrocycles such as calixarenes and cucurbiturils are increasingly
applied as mediators of protein assembly and crystallization. The macrocycle
can facilitate assembly by providing a surface on which two or more proteins
bind simultaneously. This work explores the capacity of the sulfonato-
calix[n]arene (sclxn) series to effect crystallization of PAF, a small, cationic
antifungal protein. Co-crystallization with sclx4, sclx6 or sclx8 led to high-
resolution crystal structures. In the absence of sclxn, diffraction-quality crystals
of PAF were not obtained. Interestingly, all three sclxn were bound to a similar
patch on PAF. The largest and most flexible variant, sclx8, yielded a dimer of
PAF. Complex formation was evident in solution via NMR and ITC experiments,
showing more pronounced effects with increasing macrocycle size. In agreement
with the crystal structure, the ITC data suggested that sclx8 acts as a bidentate
ligand. The contributions of calixarene size/conformation to protein recognition
and assembly are discussed. Finally, it is suggested that the conserved binding
site for anionic calixarenes implicates this region of PAF in membrane binding,
which is a prerequisite for antifungal activity.
1. Introduction
There is growing interest in the use of synthetic macrocycles as
mediators of protein assembly (van Dun et al., 2017). The
special case of protein crystallization (McPherson et al., 2011)
has benefitted from ‘molecular glues’ such as calixarenes and
cucurbiturils that promote crystal packing (Guagnini et al.,
2018; Rennie et al., 2018). The sulfonato-calix[n]arenes (sclxn,
Fig. 1) are highly water-soluble, anionic macrocycles with
diverse applications in the biosciences (Baldini et al., 2017;
Giuliani et al., 2015; Guo & Liu, 2014). The hydrophobic core
and the anionic rim of the calixarene can facilitate protein
recognition, in particular, via the entrapment of arginine or
lysine side chains (McGovern et al., 2012, 2014, 2015; Wang et
al., 2016; Mallon et al., 2016; Rennie et al., 2017, 2018; Doolan
et al., 2018; Alex et al., 2018). Consequently, sclx4 and related
compounds readily co-crystallize with the highly cationic
cytochrome c and lysozyme (Alex et al., 2018; Doolan et al.,
2018; McGovern et al., 2012, 2014, 2015). With increasing
calixarene size there tends to be more pronounced effects; for
example, phosphonato-calix[6]arene (pclx6) has an approxi-
mately tenfold increase in affinity (with respect to sclx4) and
prompts dimerization of cytochrome c in solution (Rennie et
al., 2017). Sulfonato-calix[8]arene (sclx8) on the other hand
induces a tetramer of cytochrome c (Rennie et al., 2018).
Furthermore, while calix[4]arene is locked in a bowl confor-
mation, the larger calixarenes are flexible and adopt various
conformations (Fig. 1) (Atwood et al., 1992; Dalgarno et al.,
2003; Gutsche & Bauer, 1985; Liu et al., 2009; Perret et al.,
2006; Rennie et al., 2017, 2018; Smith et al., 2006). Accordingly,
sclx8 can bind to cytochrome c either via an extended ‘pleated
loop’ or a collapsed ‘double cone’ conformation, as shown
using X-ray crystallography (Rennie et al., 2018).
We were motivated to characterize the sclxn series with a
single protein and thus investigate systematically how the
calixarene size and flexibility influence protein recognition
and assembly. Furthermore, we were interested in studying a
protein for which a crystal structure was not available.
Acknowledging the tendency of sclxn to complex cationic
proteins we chose the Penicillium antifungal protein (PAF)
(Marx et al., 1995, 2008) as a test case. PAF is a small
(6.2 kDa, 55 residues) lysine-rich protein (13  Lys, pI ’ 9)
and a potent agent against Aspergillus species and dermato-
phytes (Binder et al., 2010; Leiter et al., 2005; Palicz et al.,
2016). The NMR structure is a twisted -barrel composed of
five antiparallel -strands and stabilized by three disulfide
bridges (Batta et al., 2009; Fizil et al., 2015, 2018). Lys30,
Phe31, Lys34, Lys35 and Lys38 (loop 3) belong to a conserved
region of PAF that is important for antifungal activity (Batta et
al., 2009; Sonderegger et al., 2016; Garrigues et al., 2017).
Similar to defensins, the mechanism of antifungal action is
postulated to require interaction with anionic components on
the cell membrane (Binder et al., 2010; Garrigues et al., 2017;
Silva et al., 2014). Recent X-ray crystal structures have
revealed how defensin–phospholipid binding leads to oligo-
merization, suggesting a mechanism for membrane permea-
tion (Poon et al., 2014; Kvansakul et al., 2016; Cools et al., 2017;
Ja¨rva˚ et al., 2018). These observations provided further moti-
vation to characterize PAF binding with anionic receptors.
Here, we report three PAF–sclxn crystal structures,
demonstrating the fitness of calixarenes as crystallization
agents. Interestingly, all three calixarenes were bound to PAF,
mainly at the conserved loop 3. A similar interaction site was
determined by NMR studies; these results suggest that loop 3
is favoured for recognition by anionic receptors. The largest
calixarene sclx8 mediated a PAF dimer that was observed both
crystallographically and in solution. The thermodynamics of
PAF–sclxn interactions were characterized by isothermal
titration calorimetry, providing further evidence of PAF
dimerization via sclx8. The results are discussed in the context
of protein assembly and membrane binding. Finally, insights
into protein complexation by flexible calixarenes are
provided, including the role of PEG fragments at the protein–
calixarene interface.
2. Experimental
2.1. Materials
PAF was produced as described (Batta et al., 2009;
Sonderegger et al., 2016). The calixarenes were purchased
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Figure 1
Sulfonato-calix[n]arenes. (a) Molecular structures and (b) cone (sclx4), double partial-cone (sclx6) and double cone (sclx8) conformations.
from TCI Chemicals. Stock solutions of sclx4, sclx6 and sclx8
were prepared in water and the pH was adjusted to 6.0.
2.2. Crystallization trials
Co-crystallization experiments were performed by the
hanging-drop vapour-diffusion method at 20C. The reservoir
solution was 20–30% PEG 3350 and 50 mM sodium acetate,
pH 5.6. A range of protein (0.7–7.0 mM PAF) and ligand (5–
40 mM sclx4) concentrations were tested for PAF–sclx4 co-
crystallization. Drops were prepared by combining sequen-
tially 1 ml each of reservoir solution, protein and sclx4. Crystals
grew at 7 mM PAF and 40 mM sclx4. In the case of PAF–sclx6
and PAF–sclx8, the protein–ligand solutions were premixed
before combining with the reservoir solution. Co-crystals were
obtained with 10 mM sclx6 and 40 mM sclx8. Crystals grew in
4–5 days (sclx4), 2–3 weeks (sclx6) or 6–8 weeks (sclx8).
The crystallization of ligand-free PAF (7 mM) was
performed with an Oryx 8 Robot (Douglas Instruments) and a
sparse matrix screen (JCSG++, Jena Bioscience). Spherulites
were obtained in C6 (40% PEG 300, 100 mM potassium
phosphate citrate pH 4.2) and needles grew in D7 (40% PEG
400, 100 mM Tris–HCl pH 8.5, 200 mM lithium sulfate).
Manual crystallization trials under these conditions did not
yield suitable crystals.
2.3. X-ray data collection
Crystals were cryo-protected in reservoir solution supple-
mented with 20% glycerol and cryo-cooled in liquid nitrogen.
Diffraction data were collected at the SOLEIL synchrotron
(France) to 1.30, 1.45 and 1.50 A˚ for PAF–sclx4, PAF–sclx6 and
PAF–sclx8, respectively. Datasets were collected using ’ scans
of 0.1 over 200 (PAF–sclx4), 180 (PAF–sclx6) and 110
(PAF–sclx8) using an EIGER X 9M detector. In the case of
pure PAF, a dataset extending to 3.0 A˚ was collected for the
spherulites (condition C6), but was difficult to index/integrate
in both XDS and iMOSFLM. The needle-like crystals
(condition D7) did not diffract.
2.4. Structure determination
The observed reflections for PAF–sclx4 were processed with
XDS (Kabsch, 2010), whereas iMOSFLM (Battye et al., 2011)
was used for the PAF–sclx6 and PAF–sclx8 datasets. In all
cases, the data were scaled using POINTLESS (Evans, 2011)
and AIMLESS (Evans & Murshudov, 2013). Xtriage
(PHENIX, Adams et al., 2010) suggested pseudo-merohedral
twinning for the PAF–sclx4 data with twin law h, k, h l,
and estimated twin fractions of 0.025 (Britton analyses), 0.066
(H-test) and 0.022 (maximum-likelihood method). The struc-
ture was determined by molecular replacement in PHASER
(McCoy et al., 2007) by using the NMR structure (PDB
reference 2mhv, conformer 1; Fizil et al., 2015) as the search
model. A satisfactory solution (LLG, 134; TFZ, 7.4) was
obtained with a search model in which residues 1–2, 17–24 and
47–49 were deleted and all six cysteines were replaced by
alanine. The coordinates and restraints for sclx4 (ligand ID
T3Y) were added in COOT. Twin refinement did not result in
any significant improvement in the electron density. No
twinning was indicated for the PAF–sclx6 or PAF–sclx8 data.
The structures were solved by molecular replacement using
the structure of PAF–sclx4 (devoid of sclx4) as the search
model. The coordinates for sclx6 and sclx8 were built in
JLigand (Lebedev et al., 2012). High mosaic spread (0.3–0.9) in
the PAF–sclx8 dataset made it difficult to obtain better R
values. Truncating the images with high mosaicity did not help
in this respect. Iterative cycles of manual model building in
COOT (Emsley et al., 2010) and refinement in BUSTER
(Smart et al., 2012) were carried out until no further
improvements in Rfree and electron density were observed.
The final structures were validated with MolProbity (Chen et
al., 2010) and deposited in the Protein Data Bank as PAF–
sclx4 (PDB reference 6ha4), PAF–sclx6 (PDB reference 6hah)
and PAF–sclx8 (PDB reference 6haj).
2.5. Accessible surface area calculations
The effect of sclx4, sclx6 and sclx8 on the accessible surface
area (ASA) of PAF residues in the crystal packing environ-
ments was determined in AreaIMol as described previously
(Alex et al., 2018).
2.6. NMR spectroscopy
The sample conditions were 0.3 or 0.5 mM 15N-PAF in
10 mM sodium phosphate buffer at pH 6.0. NMR titrations
were performed at 298 K using 0.5–1 ml aliquots of 50 mM
stocks of sclx4, sclx6 or sclx8.
1H-15N HSQC spectra were
acquired with spectral widths of 12 p.p.m. (1H) and 19 p.p.m.
(15N) using two scans and 128 increments on a Bruker Avance-
II-500 NMR spectrometer. Ligand-induced chemical-shift
perturbations were analysed in CCPN (Delaglio et al., 1995).
2.7. Isothermal titration calorimetry and data fitting
PAF samples were dissolved in 10 mM sodium phosphate
pH 6.0. The same buffer was used to dilute stocks of sclx4
(7.1 mM, PAF 0.5 mM), sclx6 (3.6 mM, PAF 0.5 mM) and sclx8
(2.5 mM, PAF 0.3 mM) to the required concentration.
Samples were degassed prior to the titration. Measurements
were made at 25C using a Microcal ITC-200 instrument.
Titrations were performed in duplicate with similar trends
between each replicate. A single replicate from each calix-
arene was used for model fitting. Separate titrations of each
calixarene into buffer confirmed that the heats of dilution
were small, exothermic and approximately constant.
NITPIC (Keller et al., 2012) was used for baseline correc-
tion and integration of the thermograms. Pytc (Duvvuri et al.,
2018) was used to perform model fitting and parameter esti-
mation. The system of equations relating the independent
variables of the model (total concentrations) to the experi-
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mental observations (heat generated during injections) for the
single-site and bidentate-ligand models are as follows.
Single-site model,
½PTi ¼ ½Pi þ ½PLi
½LTi ¼ ½Li þ ½PLi; ð1Þ
½PLi ¼ K½Pi½Li; ð2Þ
qi ¼ VcellH ½PLi  ½PLi1ð1 vi=VcellÞ
 þ qdil; ð3Þ
where [PT]i is the total cell concentration of protein at the ith
injection (independent variable), [LT]i is the total cell
concentration of ligand at the ith injection (independent
variable), K1 is the equilibrium association constant (fit
parameter),H is the enthalpy (fit parameter) associated with
K, Vcell is the volume of the cell, vi is the volume of the ith
injection, qi is the heat generated from the ith injection
(dependent variable) and qdil is the heat of dilution (fit para-
meter, assumed to be constant)
Bidentate-ligand model,
½PTi ¼ ½Pi þ ½PLi þ 2½P2Li
½LTi ¼ ½Li þ ½PLi þ ½P2Li; ð4Þ
½PLi ¼ 2½K1½Pi½Li
½P2Li ¼ K1K2½P2i ½Li; ð5Þ
qi ¼ Vcell

H1 ½PLi  ½PLi1ð1 vi=VcellÞ
 
þ H1 þH2ð Þ ½P2Li  ½P2Li1ð1 vi=VcellÞ
 þ qdil;
ð6Þ
where K1 and K2 are the microscopic equilibrium association
constants (fit parameters), H1 and H2 are the enthalpies
(fit parameters) associated with K1 and K2, respectively
The expressions for mass balance of the protein and ligand
can be represented by equations (1) or (4). Equation (2) or (5)
can be used to define the equilibrium constants. For the
bidentate ligand model, equation (5) was solved numerically
(the Levenberg–Marquardt algorithm) to yield the free-
protein ([P]i) and free-ligand ([L]i) concentrations. The free
concentrations were used to compute the concentrations of
the other states via the equilibrium equations. The heat
generated from a given injection was determined using either
equations (3) or (6). Parameters were constrained to physi-
cally reasonable bounds (e.g. K1 and K2 values between 10
2
and 1010 M1) and best-fits were obtained by maximum like-
lihood starting from a range of initial estimates. Parameter
errors and correlations were estimated using a Bayesian
approach (Markov chain Monte Carlo simulations). The error
for each integrated heat was determined using NITPIC
(Keller et al., 2012).
3. Results and discussion
3.1. PAF–sclxn co-crystallization
Pure PAF proved to be recalcitrant to crystallization. A
sparse-matrix screen yielded spherulites or needle-like crystals
only (see experimental). In contrast, PAF–sclx4 mixtures were
crystallized readily from solutions containing PEG and
sodium acetate. PAF–sclx4, PAF–sclx6 and PAF–sclx8 co-
crystals were obtained at 28–30% PEG 3350 and 50 mM
sodium acetate pH 5.6 (Fig. S1 and Table S1 of the supporting
information).
3.2. Data collection and model building
Datasets extending to 1.30, 1.45 and 1.50 A˚ resolution were
collected from monoclinic (P1211) PAF–sclx4, PAF–sclx6 and
hexagonal (P61) PAF–sclx8 co-crystals, respectively (Table
S1). The PAF–sclx4 structure was determined using the NMR
coordinates (PDB reference 2mhv; Fizil et al., 2015) as the
search model. To obtain a satisfactory solution it was neces-
sary to delete two loops and replace all six cysteines with
alanines. After several rounds of model building and refine-
ment a complete PAF structure was obtained. This model was
used to solve the PAF–sclx6 and PAF–sclx8 structures. The
PAF fold and the three disulfide bridges in the X-ray struc-
tures were consistent with the NMR model (Batta et al., 2009;
Fizil et al., 2015, 2018). Interestingly, the fold was altered
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Figure 2
Binding-site interactions in PAF–sclxn. (a) sclx4, (b) sclx6 and (c) sclx8 binding to PAF at Lys30. Note the altered conformations of Lys30 and Phe31 in
each structure, while Pro29 provides a rigid hydrophobic surface for face-to-face interaction with sclx6 and sclx8. In PAF–sclx8, two protein chains
interact with the calixarene. PEG fragments equivalent to tetraethylene glycol and heptaethylene glycol were bound to sclx6 and sclx8, respectively.
slightly in response to sclxn binding (Fig. S2). Superposition of
the three structures revealed a C r.m.s.d. of 0.54 A˚ (PAF–
sclx6) and 0.78 A˚ (PAF–sclx8) relative to PAF–sclx4, with the
largest differences at loops 2, 3 and 4. The calculated energies
of the disulfide bonds (Schmidt et al., 2006) were approxi-
mately threefold lower in the X-ray structures compared with
the NMR structure (Table S2).
In contrast to the PAF–sclxn crystals, the spherulites and
needles of pure PAF failed to provide a usable dataset. The
needles did not diffract and the spherulites yielded a 3.0 A˚
resolution dataset which proved difficult to index and inte-
grate. The difficulty in obtaining suitable
crystals of pure PAF suggests that the calix-
arene facilitates protein assembly and crys-
tallization (Alex et al., 2018; Doolan et al.,
2018; McGovern et al., 2012, 2014, 2015;
Rennie et al., 2017, 2018).
3.3. Different calixarene, similar binding site
The asymmetric unit of the PAF–sclxn
complexes comprised one (in the case of PAF–
sclx4 and PAF–sclx6) or two (PAF–sclx8)
molecules of PAF. Each structure contained
one calixarene, as shown by the 2Fo—Fc
electron-density maps (Figs. 2 and S1). Addi-
tional electron density adjacent to sclx6 and
sclx8 was modelled as a PEG fragment
equivalent to tetraethylene glycol (EG4) and
heptaethylene glycol (EG7), respectively
(Figs. 2 and 3). Sclx4, locked in the cone
conformation, encapsulates the side chain of a
single lysine (Lys30), as observed previously in
different protein-clx4 complexes (Alex et al.,
2018; Doolan et al., 2018; McGovern et al.,
2012, 2014, 2015). The larger flexible sclx6 and
sclx8 adopted distinct conformations and
bound at least two lysines. Sclx6 was in the
double partial-cone conformation (Atwood et
al., 1992; Dalgarno et al., 2003), with three
sulfonates pointed upwards and three pointed
downwards [Figs. 1(b) and 2(b)]. Sclx8 adopted
the double cone conformation (Liu et al., 2009;
Perret et al., 2006; Smith et al., 2006), with each
half of the molecule acting like a calix[4]arene
to bind one PAF molecule, thus mediating a
crystallographic dimer [Fig. 2(c)].
All three calixarenes bound to Lys30, while
interacting also with neighbouring residues as
well as other proteins (symmetry mates) in the
crystal packing. Depending on the ligand size/
conformation, the noncovalent contacts varied
in their type and multiplicity. The PAF–sclx4
complex [Fig. 2(a)] was similar to cytochrome
c–sclx4 (McGovern et al., 2012), involving a
salt bridge and CH—/cation— bonds with
the encapsulated lysine. Hydrogen bonds to
the backbone amide NHs of Lys30, Phe31 and Asp32 were
evident and the aromatic ring of Phe31 was in van der Waals
contact with an sclx4 methylene bridge. Considering symmetry
mates [Fig. 4(a)], sclx4 formed substantial interfaces (>150 A˚
2)
with three proteins. Interestingly, a salt bridge was formed
with the N of Ala1. Salt bridges also occurred with Lys2,
Lys17, Lys22 and Lys35, emphasizing a substantial charge–
charge component to complexation. In total, the protein–sclx4
interfaces buried 660 A˚2 of protein.
Sclx6 (1.5 times larger than sclx4) also completely encaged
Lys30 [Fig. 2(b)]. However, one wall of the calixarene cage was
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Figure 3
Protein–PEG–calixarene interfaces. The protein–calixarene interfaces are completed by a
PEG fragment in (a) PAF–sclx6 and (b) PAF–sclx8. Lys9 N
 simultaneously forms ion–dipole
bonds to the PEG (crown-ether-like complex) and a salt bridge to one sulfonate. CH— and
lone-pair— bonds also occur between PEG and the calixarene phenolic rings.
Figure 4
Calixarenes as molecular glues. The crystal packing is dominated by PAF–sclxn interactions
in (a) PAF–sclx4, (b) PAF–sclx6 and (c) PAF–sclx8. This observation suggests that the
calixarene acts as a molecular glue in protein assembly. Proteins, calixarenes and unit-cell
axes are depicted in grey, green and blue, respectively. The PEG fragments are depicted as
sticks.
composed of three phenolic groups. The phenolic oxygens
were in van der Waals contact with the C, C and C of Lys30,
indicative of CH  O hydrogen bonding and the Lys30 N was
hydrogen bonded to a phenolic OH (rather than to a sulfo-
nate). Other differences, with respect to sclx4, were water-
mediated salt bridges between Lys30 N and two sulfonates
and a weak – interaction with Phe31 [Fig. 2(b)]. The adja-
cent residue Pro29 was also important for calixarene binding
(vide infra). In terms of crystal packing [Fig. 4(b)], the larger
sclx6 was nestled between five proteins and formed numerous
salt bridges (with Lys6, Lys9, Lys11, Lys27, Lys38, Lys42). The
resulting protein–ligand contacts mask 970 A˚2 of protein
surface. Compared with sclx4, the more extensive interactions
exhibited by sclx6 may explain why four times less ligand was
required to achieve crystal growth (see experimental and
Table S1).
The interactions of sclx8 with PAF were similar to those
observed with sclx6, though less extensive. At twice the size of
sclx4 it might be expected that sclx8 would mask a larger
protein surface; however, sclx8 formed a PAF dimer [Figs. 2(c)
and 4(c)] resulting in a total protein surface coverage of
950 A˚2. The double-cone conformation (compared with the
‘pleated loop’, Rennie et al., 2018) adopted by sclx8 minimized
its contact with protein surfaces. Salt-bridge interactions
involved up to three lysines from each monomer. Here, again a
hydrogen bond was formed between the Lys30 N and a
phenolic OH. In one of the protein chains Phe31 formed an
edge-to-face interaction with an sclx8 phenolic ring. In protein
chain B, Phe31 was disordered [Fig. 2(c)].
In complex with PAF, sclx4, sclx6 and sclx8 contributed an
additional surface of550,850 and1290 A˚2 to the protein,
respectively (calculated for a single protein). The exposed
calixarene surface is a relatively homogenous ‘mask’ that is
conducive to forming noncovalent bridges with other proteins.
Apparently, the calixarene acts as molecular glue (Fig. 4) by
providing a patch that mediates protein assembly (subse-
quently driving protein crystallization) in a special case of the
‘patchy particle model’ (Alex et al., 2018; Fusco et al., 2014;
James et al., 2015; Staneva & Frenkel, 2015; Derewenda &
Godzik, 2017).
The presence of PEG fragments (EG4 and EG7) markedly
distinguished the PAF–sclx6 and PAF–sclx8 complexes (Fig. 3).
The PEG–calixarene interaction involved lone-pair– (Jain et
al., 2009) and CH– bonds, while the PEG–protein contacts
included hydrogen bonds between the oxygen lone pairs and
Lys9 (Lys9 N  O—PEG = 3.0–3.3 A˚). This crown-ether like
Lys9–PEG interaction resembles the binding of lysine to 18-
crown-6 (PDB entry 3wur; Lee et al., 2014). A heptaethylene
glycol fragment has been observed bound to an antibody
(PDB entry 2ajs; Zhu et al., 2006), where it adopted a crown-
ether like conformation, compared with the extended
conformation in PAF–sclx8. In addition, a crystal structure of
an SH3 domain (PDB entry 5xg9; Gautam et al., 2017)
revealed various PEG fragments at protein–protein interfaces.
These examples suggest that the role of PEG is as an interface
‘filler’ and possibly the PEG fragments (Fig. 3) contribute
towards calixarene conformation selection/stability.
3.4. Selectivity of PAF–sclxn complexation, why Lys30?
Considering that PAF contains 13 lysines the question arises
as to why Lys30 was selected by sclxn. ASA calculations were
used to probe the selectivity of sclxn for the Pro29-Lys30-
Phe31 patch over other possible binding sites (Fig. 4). The
calculations accounted for contributions from symmetry mates
in the crystal packing (Alex et al., 2018). The effect of ligand
binding on the ASA of all Lys, Pro, Phe and Tyr residues is
plotted in Fig. 5. At least half of the lysines, including Lys30,
are highly exposed (ASA 	 125 A˚2) in each structure in the
absence of sclxn. This observation suggests that steric acces-
sibility (McGovern et al., 2014) was not the determining factor
in sclxn selectivity. For example, Lys2 (>150 A˚
2) was signifi-
cantly masked (ASA 	 15%) by binding with sclx4 only.
Perhaps a salt-bridge interaction with Asp46 reduced the
availability of Lys2 in the other complexes. In contrast, Lys30
was strongly affected by all three calixarenes (ASA up to
80%). Adjacent residue Lys27 was also strongly affected in the
complexes with sclx6 and sclx8. The differences in the degree
of masking can be attributed to the calixarene sizes (small,
sclx4) and conformations (‘double cone’, sclx8). However, sclx8
had more in common with sclx6 than sclx4. For example, Lys9,
Lys11 and Lys38 were 30–50% buried by sclx6 or sclx8, while
sclx4 had no effect on these residues. Overall, calixarene
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Figure 5
ASA plots. Accessibility of Lys, Pro, Phe and Tyr residues in ligand-free
(black) and ligand-bound (grey) PAF. The PAF–sclx8 data correspond to
chain A.
binding resulted in significant masking of five (sclx4), eight
(sclx6) and six (sclx8) lysines.
PAF has five aromatic residues, Phe25, Phe31, Tyr3, Tyr16
and Tyr48 (Fig. 5); the latter is highly solvent exposed
(200 A˚2) and might be expected to interact with sclxn.
However, only minor contributions were evident (Fig. S3).
Phe31 was the dominant aromatic residue for sclxn
complexation. The adjacent Lys30, Lys34 and Lys35 may
facilitate (via charge–charge interactions) calixarene binding
here, compared with Tyr48, which is proximal to Lys2 only.
The contribution of Pro29 merits special attention as it
completes the binding site for both sclx6 and sclx8 via face-to-
face hydrophobic stacks with a phenolic ring [Figs. 2(b) and
2(c)]. These interactions are reminiscent of polyphenol
binding to proline-rich proteins (Baxter et al., 1997; Charlton
et al., 2002; Quideau et al., 2011). The rigid pyrrolidine ring
appears to provide a stable platform for binding the ‘floppy’
sclx6 or sclx8. Thus, it is perhaps unsurprising that the only
proline residue in PAF was involved at the binding site.
As such, it appears to be the combination of the Pro29-
Lys30-Phe31 motif and adjacent lysines (charge–charge
interactions) that stabilize sclxn binding and impart selectivity.
This region has been implicated in PAF function, with
decreased antifungal activity when Phe31, Lys35 or Lys38
were mutated to Asn or Ala (Batta et al., 2009; Sonderegger et
al., 2016; Garrigues et al., 2017). The selectivity of the anionic
calixarenes for this site suggests that it may be involved in cell
membrane binding and permeation as required for antifungal
activity.
3.5. NMR characterization and comparison with the solid
state
PAF–calixarene binding in solution was assessed by NMR
spectroscopy. Titrations were performed by the addition of
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Figure 6
NMR characterization of PAF–sclxn complexation. (a) Region from overlaid
1H-15N HSQC spectra of pure PAF (black contours) and in the presence of
0.1–0.6 mM ligand (coloured scale). Biphasic shifts occurred for resonances Lys30, Lys34 and Cys36 in the presence of sclx6. Resonances Lys11, Cys28,
Lys30, Lys34 and Cys36 were broadened at 0.3 mM sclx8, while resonances Thr8, Lys11, Asp32 and Thr37 were broadened beyond detection at 0.6 mM
sclx8. (b) Plots of chemical-shift perturbations measured for PAF backbone amides in the presence of 0.6 mM sclx4, sclx6 or sclx8. Blanks correspond to
Pro30 and undetectable resonances (due to broadening).
microlitre aliquots of sclxn to
15N-labelled PAF, which was
monitored by 1H-15N HSQC spectroscopy (Fizil et al., 2018;
McGovern et al., 2012). The overlaid spectra (Fig. 6) revealed
increasing chemical-shift perturbations () as a function of
sclx4 or sclx6 concentration, indicative of fast to intermediate
exchange between the ligand-free and ligand-bound states.
Some biphasic shifts were evident for sclx6. Severe broadening
effects were observed with 	0.3 eq sclx8, indicative of a slow-
exchange process and suggesting the possibility of ligand-
mediated oligomerization (Doolan et al., 2018; Fonseca-
Ornelas et al., 2017; Mallon et al., 2016; Rennie et al., 2017,
2018).
The  plot (Fig. 6) shows a clear selectivity for sclx4
binding to Lys30 and neighbouring residues 31–36. In the
crystal structure, all of these residues occurred in the vicinity
of sclx4. Significant  were observed also for the C-terminal
Val52 and Cys54, which are further from the crystallographic
binding site. However, both of these residues are adjacent to
Pro29, and Cys54 is hydrogen bonded to Lys34, suggesting a
mechanism for how these resonances sense ligand binding. In
the presence of sclx6, the plot again shows a preference for
binding around Lys30 as well as effects at the C-terminus
(Val52 N is hydrogen bonded to sclx6). However, compared
with sclx4, the shifts are 2–4 times larger and other segments of
the primary structure (residues 6–13 and 42–45) were also
affected. These two regions correspond to additional sclx6
binding sites evident in the crystal packing. Therefore, the
NMR data suggests that the PAF–sclx6 interaction fluctuates,
with the calixarene exploring different patches on the protein
surface, as observed previously for cytochrome c–sclx4
complexes (Doolan et al., 2018; McGovern et al., 2012).
Judging from the magnitude of the shifts, binding to Lys30 is
preferred while a weaker interaction occurred at a patch
involving Lys6 and Lys42.
The titrations with sclx8 resulted in different effects. In
addition to pronounced perturbations of Lys30 and neigh-
bours, substantial broadening effects occurred. Cys28, Lys30,
Lys34 and Cys36 broadened at 0.3 mM, and Thr8, Lys11,
Asp32 and Thr37 broadened beyond detection at 0.6 mM
sclx8. These eight residues are located at the crystal-
lographically defined binding site. Thus, the broadening effects
may be indicative of PAF dimerization, consistent with the
sclx8-mediated dimer in the crystal structure [Fig. 2(c)].
Previously, we observed a complete loss of the HSQC spec-
trum of cytochrome c in complex with pclx6, which also
yielded a dimer in the solid state (Rennie et al., 2017).
3.6. Thermodynamics of PAF–sclxn complexation
Isothermal titration calorimetry was used to characterize
the PAF–sclxn binding affinities and stoichiometries (Fig. 7).
The data were fitted to a single-site or a bidentate-ligand
model. The latter model describes a bidentate ligand that can
bind two protein molecules and was necessary to describe the
obviously biphasic data for sclx8. The choice of this model is
supported by the observation of a PAF–sclx8–PAF dimer in
the crystal structure, and by the spectral broadening in the
NMR experiments. All of the fit parameters were well deter-
mined by the data (Table 1), with parameter errors assessed by
Bayesian methods (Patil et al., 2010).
The isotherms for sclx4 injected into PAF were fitted to a
single-site binding model with Kd 110 mM. In contrast, the
isotherms for sclx8 were biphasic (Brautigam, 2015) and fitted
to a bidentate ligand model with Kd values of 10 and
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Figure 7
ITC analysis of PAF–sclxn complexation. Top panels show the baseline-corrected thermograms for injections of sclx4, sclx6 or sclx8 into PAF. Bottom
panels are the observed heats (data points) and the fits (solid line) for single-site (sclx4) and bidentate-ligand (sclx8) models.
30 mM, for binding the first and second molecule of PAF,
respectively. The isotherms for sclx6 were intermediate
between sclx4 and sclx8, suggesting that this ligand may exhibit
weak bidentate binding. A satisfactory fit for this data was not
obtained with either model. The ITC data demonstrate an
increasing affinity for PAF as the calixarene size increases and
a switch in binding mode from the small, rigid sclx4 (single
site) to the large, flexible sclx8 (bidentate).
4. Conclusions
Using a combination of X-ray crystallography and NMR
spectroscopy it was demonstrated that the sclxn series binds
selectively to the highly cationic PAF. Despite the varying size
and conformational flexibility, sclx4, sclx6 and sclx8 bound
similarly the Pro29-Lys30-Phe31 motif in loop 3. The selec-
tivity of the anionic calixarenes for this motif, and the role of
loop 3 in antifungal activity, suggests that this region may be
required for membrane binding. In addition to charge–charge
interactions (showed by numerous lysine-to-sulfonate salt
bridges), other noncovalent bonds including CH– and –
(via Pro29 and Phe31, respectively) participated in ligand
stabilization. The presence of PEG fragments at the protein–
sclx6 and protein–sclx8 interfaces suggests that PEG acts as a
‘filler’ to complete the binding site, potentially reinforcing the
calixarene conformation.
The structures of all three PAF–sclxn co-crystals highlight
the potential of calixarenes as a ‘sticky patch’ on the protein
surface that facilitates assembly and crystallization. In the case
of the sclx4 and sclx6 co-crystals (P1211), it is evident that the
calixarene is a dominant contributor to the crystal packing
(Fig. 4). Similarly in the sclx8 structure (P61), the packing
involves substantial protein–calixarene contacts, and the
structure is interesting as sclx8 mediates a PAF dimer.
Previously, we found that sclx8 mediates a tetramer of cyto-
chrome c (Rennie et al., 2018). Generally, it seems that calix-
arene-mediated protein crystallization may be a special case of
the patchy particle model for protein assembly (Alex et al.,
2018; Fusco et al., 2014; James et al., 2015; Staneva & Frenkel,
2015; Derewenda & Godzik, 2017). Considering that PAF
alone did not yield diffraction-quality crystals, we conclude
that co-crystallization with sclxn was beneficial. Anionic
calixarenes may generally facilitate crystallization and struc-
ture determination of small cationic proteins.
The binding surfaces observed in the NMR experiments
were consistent with the X-ray data. However, the NMR
effects were more pronounced with increasing calixarene size,
suggesting that the larger calixarenes mask a greater portion
of the protein surface and/or lead to assembly in solution.
Similarly, the ITC experiments revealed tighter affinities and
more complex effects with increasing calixarene size. In
particular, sclx8 behaved as a bidentate ligand that facilitated
PAF dimerization. These data add to the growing evidence of
calixarene-mediated protein assembly in solution (Doolan et
al., 2018; Rennie et al., 2017, 2018). In terms of the biological
relevance of these data it is noted that defensin oligomeriza-
tion (upon phospholipid binding) has implications for anti-
fungal activity (Poon et al., 2014; Ja¨rva˚ et al., 2018). Perhaps
calixarenes can be used to modulate the activity of PAF and
related proteins.
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